Summary
We have evaluated the activity of ifosfamide in 75 patients with recurrent sarcomas and pediatric solid tumors. All patients had previously received cyclophosphamide in combination with other chemotherapeutic agents. Ifosfamide was administered as a continuous 5 day infusion at a dose of 1800 mg per M2, except in the last 14 patients who received the drug as a daily one hour infusion at the same dose level. Partial response was observed in 9 of 20 patients with Ewing's sarcoma, 2 of 9 patients with rhabdomyosarcoma, 3 of 17 patients with osteogenic sarcoma and 4 of 29 patients with various other neoplasms. A further 6 patients had stable disease, defined as the absence of progression for at least 6 cycles of therapy. Thus overall response rate was 24%, with the highest response rate of 45% being observed in Ewing's sarcoma. Toxicity was acceptable, although there was quite marked leucopenia (median nadir 700) with less profound thrombocytopenia (median nadir 87 000). Sepsis occurred in 3 patients but no patient died as a result of infection. Hematuria occurred in 43% of patients who did not receive mesna, and in 26% of patients who did, although prior pelvic irradiation was found to be a significant risk factor for hematuria. Only 1 of 14 patients whithout prior pelvic irradiation or hematuria developed hemorrhagic cystitis when treated with ifosfamide and mesna. Confusional states developed in 6 patients. We conclude that ifosfamide is an active agent in patients with relapsed sarcomas and childhood solid tumors, even when such patients have been previously treated with cyclophosphamide.
Similar content being viewed by others
References
Bierbaum W, Bremer K, Firusian N, Higi M, Niederle N, Scheulen ME, Schmidt CG, Seeber S (1981) Chemotherapeutische Behandlungsmöglichkeiten bei fortgeschrittenen Sarkomen. Dtsch Med Wochenschr 37: 4181–1185
Bramwell V, Mouridsen H, Santoro A, Blackledge G, Somers R, Thomas D, Sylvester R, Bush H (1985) Cyclophosphamide vs Ifosfamide: a randomised phase II trial in adult soft tissue sarcoma. Preliminary report of the EORTc soft tissue and bone sarcoma group. Proc Amer Soc Clin Oncol 4: 142 (Abst C-556)
Brock N, Habs M, Pohl J, Schmähl D, Stekar J (1982), Mesna (natrium-2-mercaptoethanesulphonate). Dtsch Therapiewoche 32: 4977–4996
Bruhl P, Gunther U, Hoefer-Janker H (1976) Results obtained with fractionated ifosfamide massive-dose treatment in generalized malignant tumors. Int J Clin Pharmacol 14: 29–39
Goldin A (1982) Ifosfamide in experimental tumor systems. Semin Oncol 9: 14–23
Hunter HL, Harrison EF (1982) The anticancer spectrum of ifosfamide. Semin Oncol 9: 96–100
Jurgens H, Csherati M, Gobel V, Gutjahr P, Jobke A, Kaatsch P, Kuhl J, Sekera J, Winkler K (1983) Die Kooperative Ewing-Sarkom-Studie CESS 81 der GPO: Zwischenbericht. Klin Padiatr 195: 207–213
Kraker J de, Voute PA (1984) Ifosfamide and vincristine in paediatric tumours. A Phase II study. Eur Pediatr Haematol Oncol 1: 47–50
Miser JS, Steis R, Longo DL, Belasco JB, Triche TJ, Kinsella TJ (1985) Treatment of newly diagnosed high-risk sarcomas and primitive neuroectodermal tumors (PNET) in children and young adults. Proc Amer Soc Clin Oncol 4: 240 (Abst C-935)
Scheulen ME, Niederle N, Bremer K, Schütte J, Seeber S (1983) Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II study with 151 patients. Cancer Treat Rev 10: 93–101
Stuart-Harris RC, Harper PG, Parsons CA, Kaye SB, Mooney CA, Gowing NF, Wiltshaw E (1983) High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft tissue sarcoma. Cancer Chemother Pharmacol 11: 69–72
Wellens W, Donhuijsen-Ant R, Habets L, Kleinmanns G, Mussgnug G, Schroeder M, Westerhausen M (1981) Therapie progredienter Sarkome mit Etoposid und Ifosfamid. Aktuel Onkol 4: 159–164
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Magrath, I., Sandlund, J., Raynor, A. et al. A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people. Cancer Chemother. Pharmacol. 18 (Suppl 2), S25–S28 (1986). https://doi.org/10.1007/BF00647446
Issue Date:
DOI: https://doi.org/10.1007/BF00647446